January 21, 2020
Pfizer on January 20 launched its biosimilar version of Roche/Chugai’s big-seller cancer drug Rituxan (rituximab) in Japan, the second such follow-on after one by Sandoz/Kyowa Kirin, which has been available on the market since January 2018. Rituximab BS IV Infusion...read more